What We Do

SJA executes deal structures with strategic partners seeking to outsource R&D through both traditional and novel partnership models, including:

  • Traditional in-licensing (“buy-side”) and out-licensing (“sell-side”) transactions.
  • Direct external innovation models, including venture co-creation partnerships—where large pharma collaborates with venture capital firms at early stages of company or project development.
  • Built-to-buy structures for asset-centric startups, involving pre-defined acquisition rights triggered upon partner nomination or milestone achievement.

Out-Licensed South Korean Rights to Salarius / Iterion’s Oncology Small Molecules

  • Negotiated licensing terms – upfront payments, milestones, royalties
  • Established joint research committees monitoring progress and report findings to board members